Patient-specific Quality Assurance Measurements Research Articles

Evaluation of 2D ion chamber arrays for patient specific quality assurance using a static phantom at a 0.35 T MR-Linac

IntroductionPatient specific quality assurance (QA) in MR-Linacs can be performed with MR-compatible ion chamber arrays. However, the presence of a static magnetic field can alter the angular response of such arrays substantially. This works investigates the suitability of two ion chamber arrays, an air-filled and a liquid-filled array, for patient specific QA at a 0.35 T MR-Linac using a static phantom. MethodsIn order to study the angular response, the two arrays were placed in a static, solid phantom and irradiated with 9.96 × 9.96 cm2 fields every 10° beam angle at a 0.35 T MR-Linac. Measurements were compared to the TPS calculated dose in terms of gamma passing rate and relative dose to the central chamber. 20 patient specific quality assurance plans were measured using the liquid-filled array. ResultsThe air-filled array showed asymmetric angular response changes of central chamber dose of up to 18% and down to local 3 mm / 3% gamma rates of 20%, while only minor differences within 3% (excluding parallel irradiation and beams through the couch edges) were found for the liquid-filled ion chamber array without rotating the phantom. Patient plan QA using the liquid-filled array yielded a median local 3 mm / 3% 3D gamma passing rate of 99.8% (range 96.9%–100%) ConclusionA liquid-filled ionization chamber array in combination with a static phantom can be used for efficient patient specific plan QA in a single measurement set-up in a 0.35 T MR-Linac, while the air-filled ion chamber array phantom shows large angular response changes and has its limitations regarding patient specific QA measurements

Can Advanced Radiotherapy Clinical Trials be Conducted in Resources Limited Countries?

The Lancet Oncology Commission on Cancer in Sub-Saharan Africa (SSA) highlighted the region's increasing cancer incidence and mortality, and recommended a series of actions to address this growing crisis. One such approach recommended by the Commission to increase access to curative treatment is the use of hypofractionated radiotherapy (HFRT). Here we highlight the barriers and facilitators to launching HFRT in SSA, as identified through the HypoAfrica clinical trial. HypoAfrica is a longitudinal multi-center clinical trial that was launched in late 2021 at three centers in Nigeria, Tanzania, and South Africa. The goal of HypoAfrica was to assess the feasibility of implementing HFRT for localized prostate cancer in SSA. To date, 155 of 182 subjects have been enrolled in this study. During the last year, a team of radiation oncology professionals from Africa, Europe, Australia, and USA met once every Saturday and reviewed the sites' data to identify the barriers to the implementation of HFRT and find solutions to overcome these challenges. With the intent to expand HFRT trials and practice to new SSA countries and radiotherapy centers, we also conducted an online survey to elucidate the readiness of radiotherapy centers across SSA to perform HFRT. The major challenge identified by this team was securing high-quality data that will yield statistically significant results. Factors that contribute to quality data are: harmonization of machine and patient-specific quality assurance (QA) procedures across the centers, data quality harmonization, and challenges associated with machine maintenance. Immediate solutions implemented included introduction of low-cost QA tools for patient-specific QA measurements, ongoing training of the site's healthcare professionals, implementation of preventative maintenance for Linacs, and data centralization infrastructure. These actions have resulted in the production of a high-quality, standardized dataset. Planned longer-term solutions to HFRT challenges include implementation of ongoing training, telehealth for remote support and QA, and the creation of an Imaging and Radiation Oncology Core for Africa. The online survey indicated that 61% of respondents' institutions perform HFRT for palliative purposes, emphasizing the readiness of sites in SSA to utilize HFRT for curative purposes. The study serves as a useful guide for increasing access to HFRT treatment in resource-limited settings and for conducting multicenter radiotherapy clinical trials.

TUNING AND VALIDATION OF THE NEW RADCALC 3D MONTE CARLO BASED PRE-TREATMENT PLAN VERIFICATION TOOL

Verification procedures for patient-specific quality assurance (QA) in advanced radiotherapy are laborious and time-consuming. Moreover, it has been shown that these procedures cannot detect some inaccuracies for some particular complex cases due to tissue inhomogeneity and highly modulated plans. Secondary dose calculation verification of radiotherapy plans is an important aspect in patient-specific QA. A suitably optimized software, RadCalc equipped with 3D Monte Carlo Module (MC), was used to dosimetrically verify radiotherapy treatment plans where the measured dose distributions can be inaccurate due to the TPS dose calculation algorithm and/or treatment unit delivery uncertainties. MC Models were built using specific commissioning measurements and then the Additional Radiation to Light Field Offset parameter (Dosimetric Leaf Gap parameter) was tuned to achieve the best dose comparison agreement with phantom patient-specific QA measurements. The results showed a good agreement between the TPS and the simulations. RadCalc MC also allows to better estimate the plan doses in lung cancer patients and to detect the presence of possible inaccuracies due to tissue inhomogeneity, which is not estimable with a homogeneous phantoms.

Correction factors for commissioning and patient specific quality assurance of stereotactic fields in a Monte Carlo based treatment planning system

Validation of small field dosimetry is crucial for stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). Accurate and considered measurement of linear accelerator dose must be compared to precise and accurate calculation by the treatment planning system (TPS). Monte Carlo calculated distributions contain statistical noise, reducing the reliance that should be given to single voxel doses. The average dose to a small volume of interest (VOI) can minimise the influence of noise, but for small fields introduces significant volume averaging. Similar challenges present during measurement of composite dose from clinical plans when a small volume ionisation chamber is used. This study derived correction factors for VOI averaged TPS doses calculated for small fields, allowing correction to an isocentre dose following account for statistical noise. These factors were used to determine an optimal VOI to represent small volume ionisation chambers during patient specific quality assurance (PSQA). A retrospective comparison of 82 SRS and 28 SBRT PSQA measurements to TPS calculated doses from varying VOI was completed to evaluate the determined volumes. Small field commissioning correction factors of under 5% were obtained for field sizes of 8 mm and larger. Optimal spherical VOI with radius between 1.5 and 1.8 mm and 2.5 to 2.9 mm were determined for IBA CC01 and CC04 ionisation chambers respectively. Review of PSQA confirmed an optimal agreement between CC01 measured doses and a volume of 1.5 to 1.8 mm while CC04 measured doses showed no variation with VOI.

A measurement validation of improved plan deliverability with monitor unit objective tool for spine stereotactic ablative radiotherapy.

Spine stereotactic body radiation therapy (SBRT) uses high dose per fraction for palliative pain control. The treatment plans are often heavily modulated due to close proximity to spinal cord and this can lead to poor plan quality which are susceptible to dose delivery discrepancy. Therefore, we aim to assess the effectiveness of the monitor unit (MU) objective tool in Eclipse treatment planning systems in modulating the plan complexity to improve the plan quality in spine SBRT. Seven retrospective spine SBRT plans are re-optimized using the MU objective tool in Eclipse TPS v13.6 and were compared with the original plans. The dose metrics of the tumor PTV were compared using D1cc. D99%, D95%, D0.03cc, D0.1cc, D0.35cc and D1cc, and that of cord PRV were compared using D0.03cc, D0.1cc, D0.35cc. Four different plan complexities were also calculated for the original and re-optimized plans to quantify the impact of the tool on the modulation. Patient specific quality assurance measurements were performed with Stereophan and SRS MapCheck, and analyzed using the 1%/1-mm and 2%/2-mm criteria with gamma analysis. The dose metrics of the PTV and cord PRV of the re-optimized and original plans are similar and still meet the planning dose constraints. In particular, the PTV dose coverage has a small percentage difference of (0.15 ± 1.33)% and (0.01 ± 1.04)% for D99% and D95%, respectively. The 4 calculated plan complexity metrics consistently show that the re-optimized plans are quantitatively less complex than the original plan. The gamma passing rate of the re-optimized plans improved from (92.2 ± 2.0)% to (94.2 ± 1.6)% with the 1%/1-mm criterion, and (98.7 ± 1.0)% to (99.5 ± 0.3)% with the 2%/2-mm criterion. Overall, the re-optimized plans achieve at least a 10% MU reduction (11.7% to 24.6%). Our study shows that optimization with the MU objective tool can reduce plan complexity and improves dose delivery accuracy, while not compromising the dose distribution.

Do we need patient-specific QA for adaptively generated plans? Retrospective evaluation of delivered online adaptive treatment plans on Varian Ethos.

The clinical introduction of dedicated treatment units for online adaptive radiation therapy (OART) has led to widespread adoption of daily adaptive radiotherapy. OART allows for rapid generation of treatment plans using daily patient anatomy, potentially leading to reduction of treatment margins and increased normal tissue sparing. However, the OART workflow does not allow for measurement of patient-specific quality assurance (PSQA) during treatment delivery sessions and instead relies on secondary dose calculations for verification of adapted plans. It remains unknown if independent dose verification is a sufficient surrogate for PSQA measurements. To evaluate the plan quality of previously treated adaptive plans through multiple standard PSQA measurements. This IRB-approved retrospective study included sixteen patients previously treated with OART at our institution. PSQA measurements were performed for each patient's scheduled and adaptive plans: five adaptive plans were randomly selected to perform ion chamber measurements and two adaptive plans were randomly selected for ArcCHECK measurements. The same ArcCHECK 3D dose distribution was also sent to Mobius3D to evaluate the second-check dosimetry system. All (n=96) ion chamber measurements agreed with the planned dose within 3% with a mean of 1.4% (±0.7%). All (n=48) plans passed ArcCHECK measurements using a 95% gamma passing threshold and 3%/2mm criteria with a mean of 99.1% (±0.7%). All (n=48) plans passed Mobius3D second-check performed with 95% gamma passing threshold and 5%/3mm criteria with a mean of 99.0% (±0.2%). Plan measurement for PSQA may not be necessary for every online-adaptive treatment verification. We recommend the establishment of a periodic PSQA check to better understand trends in passing rates for delivered adaptive treatments.

Treatment plan prescreening for patient-specific quality assurance measurements using independent MonteCarlo dose calculations.

This study proposes a method to identify plans that failed patient-specific quality assurance (QA) and attempts to establish a criterion to prescreen treatment plans for patient-specific QA measurements with independent Monte Carlo dose calculations. Patient-specific QA results measured with an ArcCHECK diode array of 207 patients (head and neck: 25; thorax: 61; abdomen: 121) were retrospectively analyzed. All patients were treated with the volumetric modulated arc therapy (VMAT) technique and plans were optimized with a Pinnacle v16.2 treatment planning system using an analytical algorithm-based dose engine. Afterwards, phantom verification plans were designed and recalculated by an independent GPU-accelerated Monte Carlo (MC) dose engine, ArcherQA. Moreover, sensitivity and specificity analyzes of gamma passing rates between measurements and MC calculations were carried out to show the ability of MC to monitor failing plans (ArcCHECK 3%/3mm,<90%), and attempt to determine the appropriate threshold and gamma passing rate criterion utilized by ArcherQA to prescreen treatment plans for ArcCHECK measurements. The receiver operator characteristic (ROC) curve was also utilized to characterize the performance of different gamma passing rate criterion used by ArcherQA. The thresholds for 100% sensitivity to detect plans that failed patient-specific QA by independent calculation were 97.0%, 95.4%, and 91.0% for criterion 3%/3mm, 3%/2mm, and 2%/2mm, respectively, which corresponded to specificities of 0.720, 0.528, and 0.585, respectively. It was shown that the 3%/3mm criterion with 97% threshold for ArcherQA demonstrated perfect sensitivity and the highest specificity compared with other criteria, which may be suitable for prescreening treatment plans treated with the investigated machine to implement measurement-based patient-specific QA of patient plans. In addition, the area under the curve (AUC) calculated from ROC analysis for criterion 3%/3mm, 3%/2mm, and 2%/2mm used by ArcherQA were 0.948, 0.924, and 0.929, respectively. Independent dose calculation with the MC-based program ArcherQA has potential as a prescreen treatment for measurement-based patient-specific QA. AUC values (>0.9) showed excellent classification accuracy for monitoring failing plans with independent MC calculations.

Clinical utility of Gafchromic film in an MRI-guided linear accelerator

BackgroundThe purpose of this study is to comprehensively evaluate the suitability of Gafchromic EBT3 and EBT-XD film for dosimetric quality assurance in 0.35 T MR-guided radiotherapy.MethodsA 0.35 T magnetic field strength was utilized to evaluate magnetic field effects on EBT3 and EBT-XD Gafchromic films by studying the effect of film exposure time within the magnetic field using two timing sequences and film not exposed to MR, the effect of magnetic field exposure on the crystalline structure of the film, and the effect of orientation of the film with respect to the bore within the magnetic field. The orientation of the monomer crystal was qualitatively evaluated using scanning electron microscopy (SEM) compared to unirradiated film. Additionally, dosimetric impact was evaluated through measurements of a series of open field irradiations (0.83 × 0.83-cm2 to 19.92 × 19.92-cm2) and patient specific quality assurance measurements. Open fields were compared to planned dose and an independent dosimeter. Film dosimetry was applied to twenty conventional and twenty stereotactic body radiotherapy (SBRT) patient specific quality assurance cases.ResultsNo visual changes in crystal orientation were observed in any evaluated SEM images nor were any optical density differences observed between films irradiated inside or outside the magnetic field for both EBT3 and EBT-XD film. At small field sizes, the average difference along dose profiles measured in film compared to the same points measured using an independent dosimeter and to predicted treatment planning system values was 1.23% and 1.56%, respectively. For large field sizes, the average differences were 1.91% and 1.21%, respectively. In open field tests, the average gamma pass rates were 99.8% and 97.2%, for 3%/3 mm and 3%/1 mm, respectively. The median (interquartile range) 3%/3 mm gamma pass rates in conventional QA cases were 98.4% (96.3 to 99.2%), and 3%/1 mm in SBRT QA cases were 95.8% (95.0 to 97.3%).ConclusionsMR exposure at 0.35 T had negligible effects on EBT3 and EBT-XD Gafchromic film. Dosimetric film results were comparable to planned dose, ion chamber and diode measurements.

Survey of patient-specific quality assurance practice for IMRT and VMAT.

A first‐time survey across 15 cancer centers in Ontario, Canada, on the current practice of patient‐specific quality assurance (PSQA) for intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) delivery was conducted. The objectives were to assess the current state of PSQA practice, identify areas for potential improvement, and facilitate the continued improvement in standardization, consistency, efficacy, and efficiency of PSQA regionally. The survey asked 40 questions related to PSQA practice for IMRT/VMAT delivery. The questions addressed PSQA policy and procedure, delivery log evaluation, instrumentation, measurement setup and methodology, data analysis and interpretation, documentation, process, failure modes, and feedback. The focus of this survey was on PSQA activities related to routine IMRT/VMAT treatments on conventional linacs, including stereotactic body radiation therapy but excluding stereotactic radiosurgery. The participating centers were instructed to submit answers that reflected the collective view or opinion of their department and represented the most typical process practiced. The results of the survey provided a snapshot of the current state of PSQA practice in Ontario and demonstrated considerable variations in the practice. A large majority (80%) of centers performed PSQA measurements on all VMAT plans. Most employed pseudo‐3D array detectors with a true composite (TC) geometry. No standard approach was found for stopping or reducing frequency of measurements. The sole use of delivery log evaluation was not widely implemented, though most centers expressed interest in adopting this technology. All used the Gamma evaluation method for analyzing PSQA measurements; however, no universal approach was reported on how Gamma evaluation and pass determination criteria were determined. All or some PSQA results were reviewed regularly in two‐thirds of the centers. Planning related issues were considered the most frequent source for PSQA failures (40%), whereas the most frequent course of action for a failed PSQA was to review the result and decide whether to proceed to treatment.

Use of Receiver Operating Curve Analysis and Machine Learning With an Independent Dose Calculation System Reduces the Number of Physical Dose Measurements Required for Patient-Specific Quality Assurance

Our purpose was to assess the use of machine learning methods and Mobius 3D (M3D) dose calculation software to reduce the number of physical ion chamber (IC) dose measurements required for patient-specific quality assurance during corona virus disease2019. In this study, 1464 inversely planned treatments using Pinnacle or Raystation treatment planning software (TPS) were delivered using Elekta Versa HD and Varian Truebeam and Truebeam STx linear accelerators between June 2018 and November 2019. For each plan, an independent dose calculation was performed using M3D, and an absolute dose measurement was taken using a Pinpoint IC inside the Mobius phantom. The point dose differences between the TPS and M3D calculation and between TPS and IC measurements were calculated. Agreement between the TPS and IC was used to define the ground truth plan failure. To reduce the on-site personnel during the pandemic, 2 methods of receiver operating characteristic analysis (n = 1464) and machine learning (n = 603) were used to identify patient plans that would require physical dose measurements. In the receiver operating characteristic analysis, a predelivery M3D difference threshold of 3% identified plans that failed an IC measurement at a 4% threshold with 100% sensitivity and 76.3% specificity. This indicates that fewer than 25% of plans required a physical dose measurement. A threshold of 1% on a machine learning model was able to identify plans that failed an IC measurement at a 3% threshold with 100% sensitivity and 54.3% specificity, leading to fewer than 50% of plans that required a physical dose measurement. It is possible to identify plans that are more likely to fail IC patient-specific quality assurance measurements before delivery. This possibly allows for a reduction of physical measurements taken, freeing up significant clinical resources and reducing the required amount of on-site personnel while maintaining patient safety.

Commissioning and clinical implementation of the first commercial independent Monte Carlo 3D dose calculation to replace CyberKnife M6™ patient-specific QA measurements.

PurposeTo report on the commissioning and clinical validation of the first commercially available independent Monte Carlo (MC) three‐dimensional (3D) dose calculation for CyberKnife robotic radiosurgery system® (Accuray, Sunnyvale, CA).MethodsThe independent dose calculation (IDC) by SciMoCa® (Scientific RT, Munich, Germany) was validated based on water measurements of output factors and dose profiles (unshielded diode, field‐size dependent corrections). A set of 84 patient‐specific quality assurance (QA) measurements for multi‐leaf collimator (MLC) plans, using an Octavius two‐dimensional SRS1000 array (PTW, Freiburg, Germany), was compared to results of respective calculations. Statistical process control (SPC) was used to detect plans outside action levels.ResultsOf all output factors for the three collimator systems of the CyberKnife, 99% agreed within 2% and 81% within 1%, with a maximum deviation of 3.2% for a 5‐mm fixed cone. The profiles were compared using a one‐dimensional gamma evaluation with 2% dose difference and 0.5 mm distance‐to‐agreement (Γ(2,0.5)). The off‐centre ratios showed an average pass rate >99% (92–100%). The agreement of the depth dose profiles depended on field size, with lowest pass rates for the smallest MLC field sizes. The average depth dose pass rate was 88% (35–99%). The IDCs showed a Γ(2,1) pass rate of 98%. Statistical process control detected six plans outside tolerance levels in the measurements, all of which could be attributed the measurement setup. Independent dose calculations showed problems in five plans, all due to differences in the algorithm between TPS and IDC. Based on these results changes were made in the class solution for treatment plans.ConclusionThe first commercially available MC 3D dose IDC was successfully commissioned and validated for the CyberKnife and replaced all routine patient‐specific QA measurements in our clinic.

Evaluation of GATE-RTion (GATE/Geant4) Monte Carlo simulation settings for proton pencil beam scanning quality assurance.

Geant4 is a multi-purpose Monte Carlo simulation tool for modeling particle transport in matter. It provides a wide range of settings, which the user may optimize for their specific application. This study investigates GATE/Geant4 parameter settings for proton pencil beam scanning therapy. GATE8.1/Geant4.10.3.p03 (matching the versions used in GATE-RTion1.0) simulations were performed with a set of prebuilt Geant4 physics lists (QGSP_BIC, QGSP_BIC_EMY, QGSP_BIC_EMZ, QGSP_BIC_HP_EMZ), using 0.1mm-10mm as production cuts on secondary particles (electrons, photons, positrons) and varying the maximum step size of protons (0.1mm, 1mm, none). The results of the simulations were compared to measurement data taken during clinical patient specific quality assurance at The Christie NHS Foundation Trust pencil beam scanning proton therapy facility. Additionally, the influence of simulation settings was quantified in a realistic patient anatomy based on computer tomography (CT) scans. When comparing the different physics lists, only the results (ranges in water) obtained with QGSP_BIC (G4EMStandardPhysics_Option0) depend on the maximum step size. There is clinically negligible difference in the target region when using High Precision neutron models (HP) for dose calculations. The EMZ electromagnetic constructor provides a closer agreement (within 0.35mm) to measured beam sizes in air, but yields up to 20% longer execution times compared to the EMY electromagnetic constructor (maximum beam size difference 0.79mm). The impact of this on patient-specific quality assurance simulations is clinically negligible, with a 97% average 2%/2mm gamma pass rate for both physics lists. However, when considering the CT-based patient model, dose deviations up to 2.4% are observed. Production cuts do not substantially influence dosimetric results in solid water, but lead to dose differences of up to 4.1% in the patient CT. Small (compared to voxel size) production cuts increase execution times by factors of 5 (solid water) and 2 (patient CT). Taking both efficiency and dose accuracy into account and considering voxel sizes with 2mm linear size, the authors recommend the following Geant4 settings to simulate patient specific quality assurance measurements: No step limiter on proton tracks; production cuts of 1mm for electrons, photons and positrons (in the phantom and range-shifter) and 10mm (world); best agreement to measurement data was found for QGSP_BIC_EMZ reference physics list at the cost of 20% increased execution times compared to QGSP_BIC_EMY. For simulations considering the patient CT model, the following settings are recommended: No step limiter on proton tracks; production cuts of 1mm for electrons, photons and positrons (phantom/range-shifter) and 10mm (world) if the goal is to achieve sufficient dosimetric accuracy to ensure that a plan is clinically safe; or 0.1mm (phantom/range-shifter) and 1mm (world) if higher dosimetric accuracy is needed (increasing execution times by a factor of 2); most accurate results expected for QGSP_BIC_EMZ reference physics list, at the cost of 10-20% increased execution times compared to QGSP_BIC_EMY.

Investigating beam matching for multi-room pencil beam scanning proton therapy.

The purpose of this study was to investigate the proton beam matching for a multi-room ProteusPLUS pencil beam scanning (PBS) proton therapy system and quantify the agreement among three beam-matched treatment rooms (GTR1, GTR2, and GTR3). In-air spot size measurements were acquired using a 2D scintillation detector at various gantry angles. Range and absolute dose measurements were performed in water at gantry angle 0°. Patient-specific quality assurance (QA) plans of four different disease sites (brain, mediastinum, sacrum, and prostate) and machine QA fields with uniform dose were delivered for various beam conditions. The results from GTR1 were considered as reference values. The average difference in spot sizes between GTR2 and GTR1 was - 0.3% ± 2.2% (range, - 5.9 to 5.8%). For GTR3 vs. GTR1, the average difference in spot sizes was 0.6% ± 1.7% (range, - 4.8 to 4.6%). The spot symmetry was found to be ≤ 4.4%. For proton range, the difference among three rooms was within ± 0.5mm. On average, the difference in absolute dose was - 0.1 ± 0.7% (range, - 1.3 to 2.1%) for GTR2 vs. GTR1 and 0.7 ± 0.6% (range, - 0.1 to 2.1%) for GTR3 vs. GTR1. The average gamma passing rate of patient-specific QA measurements (n = 29) was ≥ 98.6%. The average gamma passing rate of machine QA fields was 99.9%. In conclusion, proton beam matching was quantified for three beam-matched rooms of an IBA ProteusPLUS system with a PBS dedicated nozzle. It is feasible to match the spot size and absolute dose within ± 5% and ± 2%, respectively. Proton range can be matched within ± 0.5mm.

Dosimetric evaluation of phantoms including metal objects with high atomic number for use in intensity modulated radiation therapy.

The dosimetric effect of artefacts caused by metal hip prostheses in computed tomography imaging is most commonly encountered in the planning of prostate cancer treatment. In this study, a phantom, containing a metal with high atomic number, was prepared for intensity-modulated radiotherapy (IMRT) treatment plans to be used in quality assurance (QA) procedures. Two sets of image files, one without metal artefact correction (ORG) and another with MAR correction (MAR+), were sent to the treatment planning system. In this study, 12 IMRT treatment plans with different fields and segment numbers were calculated. The normal tissue complication probability (NTCP) values of imaginary organs at risk (OARs), such as the rectum and bladder, were investigated, as was the difference in dose maps for ORG and MAR+ derived by calculating gamma passing rates (GPRs). The MatriXX was used for the gamma evaluation of patient-specific IMRT QA measurements. The gamma evaluation was repeated, based on the measurements using an EBT3 gafchromic film, for the plan showing the lowest GPR. The mean relative difference in NTCP values between the two sets of image files was found to be 2.5, 2.1 and 1.4 for the rectum; and 5.33, 6.80 and 9.82 for the bladder, for the investigated 5-, 7- and 9-field beam arrangements, respectively. The relative differences and the standard deviations in GPRs for the standard and metal-containing phantoms were calculated for the MAR+ and ORG sets. The maximum difference found was 7.69% ± 0.88 for the 9-field beam arrangement calculated without metal artefact correction. In the IMRT QA procedures for prostate patients with hip prostheses, the application of a metal-containing phantom that is both easy and inexpensive to prepare, is considered to be a useful method for examining any dose changes involved in introducing a hip prosthesis. Therefore, it is recommended for use in clinics that do not have MAR correction algorithms.

A noise correction of the γ-index method for Monte Carlo dose distribution comparison.

Due to the increasing complexity of IMRT/IMPT treatments, quality assurance (QA) is essential to verify the quality of the dose distribution actually delivered. In this context, Monte Carlo (MC) simulations are more and more often used to verify the accuracy of the treatment planning system (TPS). The most common method of dose comparison is the γ-test, which combines dose difference and distance-to-agreement (DTA) criteria. However, this method is known to be dependent on the noise level in dose distributions. We propose here a method to correct the bias of the γ passing rate (GPR) induced by MC noise. The GPR amplitude was studied as a function of the MC noise level. A model of this noise effect was mathematically derived. This model was then used to predict the time-consuming low-noise GPR by fitting multiple fast MC dose calculations. MC dose maps with a noise level between 2% and 20% were computed, and the GPR was predicted at a noise level of 0.3%. Due to the asymmetry of the γ-test, two different cases were considered: the MC dose was first set as reference dose, then as evaluated dose in the γ-test. Our method was applied on six proton therapy plans including analytical doses from the TPS or patient-specific QA measurements. An average absolute error of 4.31% was observed on the GPR computed for MC doses with 2% statistical noise. Our method was able to improve the accuracy of the gamma passing rate by up to 13%. The method was found especially efficient to correct the noise bias when the DTA criterion is low. We propose a method to enhance the γ-evaluation of a treatment plan when there is noise in one of the compared distributions. The method allows, in a tractable time, to detect the cases for which a correction is necessary and can improve the accuracy of the resulting passing rates.

Comparison of patient-specific intensity modulated radiation therapy quality assurance for the prostate across multiple institutions.

To evaluate the success of a patient-specific intensity modulated radiation therapy (IMRT) quality assurance (QA) practice for prostate cancer patients across multiple institutions using a questionnaire survey. The IMRT QA practice involves different methods of dose distribution verification and analysis at different institutions. Two full-arc volumetric modulated arc therapy (VMAT) plan and 7 fixed-gantry IMRT plan with DMLC were used for patient specific QA across 22 institutions. The same computed tomography image and structure set were used for all plans. Each institution recalculated the dose distribution with fixed monitor units and without any modification. Single-point dose measurement with a cylindrical ionization chamber and dose distribution verification with a multi-detector or radiochromic film were performed, according to the QA process at each institution. Twenty-two institutions performed the patient-specific IMRT QA verifications. With a single-point dose measurement at the isocenter, the average difference between the calculated and measured doses was 0.5 ± 1.9%. For the comparison of dose distributions, 18 institutions used a two or three-dimensional array detector, while the others used Gafchromic film. In the γ test with dose difference/distance-to-agreement criteria of 3%-3 mm and 2%-2 mm with a 30% dose threshold, the median gamma pass rates were 99.3% (range: 41.7%-100.0%) and 96.4% (range: 29.4%-100.0%), respectively. This survey was an informative trial to understand the verification status of patient-specific IMRT QA measurements for prostate cancer. In most institutions, the point dose measurement and dose distribution differences met the desired criteria.

Predicting VMAT patient-specific QA results using a support vector classifier trained on treatment plan characteristics and linac QC metrics

The use of treatment plan characteristics to predict patient-specific quality assurance (QA) measurement results has recently been reported as a strategy to help facilitate automated pre-treatment verification workflows or to provide a virtual assessment of delivery quality. The goal of this work is to investigate the potential of using treatment plan characteristics and linac performance metrics (i.e. quality control test results) in combination with machine learning techniques to predict the results of VMAT patient-specific QA measurements.Using features that describe treatment plan complexity and linac performance metrics, we trained a linear support vector classifier (SVC) to classify the results of VMAT patient-specific QA measurements. The ‘targets’ in this model were simple classes representing median dose difference between measured and expected dose distributions—‘hot’ if the median dose deviation was >1%, ‘cold’ if it was <−1%, and ‘normal’ if it was within ±1%. A total of 1620 unique patient-specific QA measurements were available for model development and testing. 75% of the data were used to develop and cross-validate the model, and the remaining 25% were used for an independent assessment of model performance. For the model development phase, a recursive feature elimination (RFE) cross-validation technique was used to eliminate unimportant features. Model performance was assessed using receiver operator characteristic (ROC) curve metrics.Of the ten features found to be most predictive of patient-specific QA measurement results, half were derived from treatment plan characteristics and half from quality control (QC) metrics characterizing linac performance. The model achieved a micro-averaged area under the ROC curve of 0.93, and a macro-averaged area under the ROC curve of 0.88.This work demonstrates the potential of using both treatment plan characteristics and routine linac QC results in the development of machine learning models for VMAT patient-specific QA measurements.

Evaluating small field dosimetry with the Acuros XB (AXB) and analytical anisotropic algorithm (AAA) dose calculation algorithms in the eclipse treatment planning system

AbstractBackground:An increasing number of external beam treatment modalities including intensity modulated radiation therapy, volumetric modulated arc therapy (VMAT) and stereotactic radiosurgery uses very small fields for treatment planning and delivery. However, there are major challenges in small photon field dosimetry, due to the partial occlusion of the direct photon beam source’s view from the measurement point, lack of lateral charged particle equilibrium, steep dose-rate gradient and volume averaging effect of the detector response and variation of the energy fluence in the lateral direction of the beam. Therefore, experimental measurements of dosimetric parameters such as percent depth doses (PDDs), beam profiles and relative output factors (ROFs) for small fields continue to be a challenge.Materials and Methods:In this study, we used a homogeneous water phantom and the heterogeneous anthropomorphic stereotactic end-to-end verification (STEEV) head phantom for all dose measurements and calculations. PDDs, lateral dose profiles and ROFs were calculated in the Eclipse Treatment Planning System version 13·6 using the Acuros XB (AXB) and the analytical anisotropic algorithms (AAAs) in a homogenous water phantom. Monte Carlo (MC) simulations and measurements using the Exradin W1 Scintillator were also accomplished for four photon energies: 6 MV, 6FFF, 10 MV and 10FFF. Two VMAT treatment plans were generated for two different targets: one located in the brain and the other in the neck (close to the trachea) in the head phantom (CIRS, Norfolk, VA, USA). A Varian Truebeam linear accelerator (Varian, Palo Alto, CA, USA) was used for all treatment deliveries. Calculated results with AXB and AAA were compared with MC simulations and measurements.Results:The average difference of PDDs between W1 Exradin Scintillator measurements and MC simulations, AAA and AXB algorithm calculations were 1·2, 2·4 and 3·2%, respectively, for all field sizes and energies. AXB and AAA showed differences in ROF of about 0·3 and 2·9%, respectively, compared with W1 Exradin Scintillator measured values. For the target located in the brain in the head phantom, the average dose difference between W1 Exradin Scintillator and the MC simulations, AAA and AXB were 0·2, 3·2 and 2·7%, respectively, for all field sizes. Similarly, for the target located in the neck, the respective dose differences were 3·8, 5·7 and 3·5%.Conclusion:In this study, we compared dosimetric parameters such as PDD, beam profile and ROFs in water phantom and isocenter point dose measurements in an anthropomorphic head phantom representing a patient. We observed that measurements using the W1 Exradin scintillator agreed well with MC simulations and can be used efficiently for dosimetric parameters such as PDDs and dose profiles and patient-specific quality assurance measurements for small fields. In both homogenous and heterogeneous media, the AXB algorithm dose prediction agrees well with MC and measurements and was found to be superior to the AAA algorithm.

Validating a Monte Carlo approach to absolute dose quality assurance for proton pencil beam scanning

For radiotherapy, it is crucial to guarantee that the delivered dose matches the planned dose. Therefore, patient specific quality assurance (QA) of absolute dose distributions is necessary. Here, we investigate the potential of replacing patient specific QA for pencil beam scanned proton therapy with Monte Carlo simulations. First, the set-up of the automated Monte Carlo model is presented with an emphasis on the absolute dose validation. Second, the absolute dose results obtained from the Monte Carlo simulation for a comprehensive set of patient fields are compared to patient specific QA measurements. Absolute doses measured with the Farmer chamber are shown to be 1.4% higher than the doses measured with the Semiflex chamber. For single energy layers, Monte Carlo simulated doses are 2.1% ± 0.4% lower than the ones measured with the ionization chamber and 1.1% ± 1.0% lower than measurements compared to patient field verification measurements. After rescaling to account for this 1.1% discrepancy, 98 fields (94.2%) agree within 2% to measurements, the maximum difference being 2.3%. In conclusion, an automated, easy-to-use Monte Carlo calculation system has been set up. This system reproduced patient specific QA results over a wide range of cases, showing that the time consuming measurements could be reduced or even replaced using Monte Carlo simulations without jeopardizing treatment quality.

Suitability of EBT3 GafChromic film for quality assurance in MR-guided radiotherapy at 0.35 T with and without real-time MR imaging

The 0.35 T 60Co MRIdian system (ViewRay Inc., Mountain View) has been in clinical use in our institution since May 2016. For quality assurance (QA) of dose delivery and end-to-end testing for this machine, a reliable dosimeter is required. However, it is possible that a magnetic field may cause perturbations to dosimetry measurements. For static magnetic fields, there is conflicting information in the literature concerning EBT film behaviour, while for real-time MR imaging such information is not available at all. The purpose of this study was to investigate the suitability of EBT3 GafChromic film for MRIdian QA, both with and without real-time MR imaging.EBT3 film sheets were irradiated in water using the MRIdian and a conventional linear accelerator (Linac) for reference. Dose calibration measurements were first performed up to 8 Gy for both machines. The MRIdian measurements were performed with and without real-time MR imaging. Second, film sheets were irradiated at seven different angles with respect to the B0-field. Optical density and dose values were analysed for the three colour channels.In both the film dose-response and B0-field orientation measurements, the mean dose values were within the 1% uncertainty range of prescribed dose values for the red and green channels, for both machines. There were no dose deviations detected between the MRIdian and Linac film measurements, nor for different B0-field orientations. In addition, the film dose-response measurements during real-time imaging were within 1.5% of the reference Linac measurements.EBT3 GafChromic film can be used for absolute dosimetry during real-time MR imaging independent of its orientation in the B0-field. This makes it a suitable dosimeter for patient-specific QA measurements and end-to-end testing of 0.35 T MRI-radiotherapy devices.